☆ 4.5 Letter

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

BLOOD CANCER JOURNAL (2020)

Get Full Text
Add to Collection

Journal

BLOOD CANCER JOURNAL
Volume 10, Issue 9, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41408-020-00358-3

Keywords

-

Categories

Oncology Hematology

Funding

  1. Associazione Italiana Ricerca sul Cancro (AIRC) [9980]
  2. AIRC
  3. Fondazione CaRiCal - Multi-Unit Regional Grant 2014 [16695]
  4. Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant [IG-21687, IG-14326]
  5. Progetto Ricerca Finalizzata, Ministero della Salute, Rome, Italy [PE-201602362756, PE 2016-02362756, RF-2018-12365790]
  6. Italian Ministry of Health
  7. GILEAD Sciences Srl

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.